Hyper-accelerate drug development.

FDA says that by 2030 more than 50% of all dossier submissions will include In Silico evidence

InSilicoMinds In Numbers

0 +
Total Number of In Silico Regulatory Dossier Submissions filed by our team
0 +
Years in Modeling
& Simulation
0 +
Scientific
Collaborations
> 0 %
Time saved on
R&D activities

About InSilicoMinds

InSilicoMinds specializes in providing AI and advanced modeling and simulation solutions for Pharma & Life Sciences. We leverage the best of breed validated global solutions and service providers to offer the best in class in silico solutions which help our clients optimize their drug development cycle, reduce costs, save time, and improve patient outcomes. InSilicoMinds enhances its portfolio of computational solutions through an exclusive partnership with InSilicoTrials, a premier provider of AI and simulation tools for drug development, reflecting both companies’ commitment to innovation and excellence in advancing drug research and development.

We are a team of experienced life sciences, digital innovation, and in silico experts that work together to provide our in silico solution. Our team has extensive experience working with a wide range of pharmaceutical and life sciences clients, from small startups to large multinational corporations. We understand the unique challenges facing these industries, and we have the knowledge and expertise to help our clients succeed.

Expertise

  • In Silico Modeling & Simulation
  • Bioinformatics & Computational Biology/Chemistry
  • Clinical Research & In Silico Trials
  • Domain Advisory & Consultancy
  • Staff Augmentation

Our Solutions

Generics

The development of generic drugs is a complex and costly process that requires a significant investment of time and resources. Our approaches involve the use of computational methods to simulate and predict the behavior of drugs in the body, optimize drug formulations and predict potential safety issues for various dosage forms such as Solid orals, Complex injectables, Transdermal patches etc.

Vaccines

The development of vaccines is a critical component of global health efforts, but it is a complex and time-consuming process. Our computational tools can play a vital role in streamlining and de-risking vaccine development to achieve a faster process, lower costs, and higher vaccine efficacy.

Drug Discovery

The life science industry has long faced the lengthy and costly process of developing new drugs and medical devices. Digital Twin and Biosimulation are the key to cutting down time frames and costs in this area. Our digital simulations help companies reduce by up to 50% the time-consuming and costly development, as well as subsequent registration / certification processes of new drugs and medical devices.

Why we are the best choice

Our company is the best in the industry due to several differentiators that set us apart from our competitors. First and foremost, we have a strong focus on collaboration and scientific research, with over 70 partnerships in this area with regulatory agencies, academic research institutes, and healthcare organizations worldwide.

Additionally, we have access to an impressive $300+ million worth of disease models, in silico tools, and other resources that allow us to stay at the forefront of our field.

Our extensive domain experience is another key advantage, as we have worked with all types of biomedical and pharmaceutical products, including LAIs, biosimilars, vaccines, proteins/peptides, large and small molecules, NCEs/NBEs, and more.

Our validated disease models across various therapeutic areas, such as oncology and neurology, further demonstrate our commitment to providing a breadth and depth of solutions for pharmaceutical development. Finally, we are proud to be GSP compliant, which ensures that our products and services meet the highest standards of safety and quality.

Our Approach

Our AI, Modeling & Simulation experts work closely with our clients to understand their unique scientific questions of interest and challenges. We then leverage our expertise in modeling and simulation to provide innovative solutions and insights.

Our Tech Expertise

Our AI, Modeling & Simulation experts leverage a combination of best-of-breed software and proprietary in-house tools to deliver comprehensive solutions in the field of AI, modeling, and simulation.

We embody GSP
(Good Simulation Practice)
Guidelines

MODELING AND SIMULATION is a proven scientific approach used to inform crucial drug development decisions. Accepted by regulators and used across the development cycle, it integrates knowledge and relationships between the drug product, safety & efficacy, disease, patient populations and clinical trial parameters.

GxP are a collection of good practices and in the Biomedical field we have Good Laboratory (GLP), Good Clinical Practice (GCP), Good Manufacturing Practices (GMP)…and now Good Simulation Practice (GSP)

An international consortium of over 144 experts from academia, industry, and regulators—including the Avicenna Alliance, VPH Institute, the EU-funded project InSilicoWorld, and 13 M&S experts from FDA’s ModSimWG—are collaborating to establish consensus on best practices for computer modeling and simulation in regulated environments. Their collective work, “Toward Good Simulation Practice,” will be published as an open-access book by Nature Springer with Luca Emili (InSilicoTrials) and Marco Viceconti (University of Bologna) as the editors.

Toward Good Simulation Practice

Best Practices for the Use of Computational Modelling and Simulation in the Regulatory Process of Biomedical Products

Editors: Marco Viceconti, Luca Emili

Our Partners

MODELING AND SIMULATION is a proven scientific approach used to inform crucial drug development decisions. Accepted by regulators and used across the development cycle, it integrates knowledge and relationships between the drug product, safety & efficacy, disease, patient populations and clinical trial parameters.

InSilicoMinds enhances its portfolio of computational solutions through an exclusive partnership with InSilicoTrials, a premier provider of AI and simulation tools for drug development, reflecting both companies’ commitment to innovation and excellence in advancing drug research and development.

InSilicoMinds expands its influence in accelerating medicine as an esteemed Avicenna Alliance. This strategic collaboration unites key healthcare stakeholders committed to establishing in silico practices as the norm, ultimately benefiting the pharmaceutical industry and patients globally.

Knowledge Center